CerebroNeurogen

Research

CerebroNeurogen Research

CerebroNeurogen, also known as FPF 1070, is a porcine brain-derived peptide preparation with notable neurotrophic and neuroprotective properties. This neuropeptide preparation has been investigated across multiple neurological conditions.

Mechanisms of Action and Neurotrophic Effects

FPF 1070 functions as a neurotrophic factor analog with multimodal actions supporting central nervous system (CNS) function through protection, maintenance, and regeneration of neural systems.^[1]

Research has demonstrated that FPF 1070 exhibits neurotrophic effects on cultured neurons from various sources, including chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks.^[2]

The compound has also shown protective effects against delayed neuronal death in experimental models, with mechanisms involving the modulation of oxidative stress through interactions with hydroxyl radicals.^[3]

The multimodal action of FPF 1070 differentiates it from single-target compounds, potentially accounting for its broader applications across various neurological conditions with complex pathophysiologies.^[4]

Alzheimer’s Disease and Vascular Dementia

Alzheimer’s disease (AD) remains a significant global health challenge with prevalence expected to double in two decades, reaching 100 million cases worldwide.

A comprehensive umbrella review examining various treatment options for AD found that FF 1070 appears beneficial for cognitive function, global performance, and activities of daily living in AD patients.^[5] The multimodal nature of FPF 1070 may be particularly valuable in AD treatment, considering the disease’s multifactorial pathophysiology.^[4]

Multiple clinical trials have demonstrated FPF 1070’s safety and efficacy in AD treatment, with evidence suggesting both immediate therapeutic effects and potential long-term benefits that may modify disease progression.^[6]

A Cochrane review analyzing six randomized controlled trials with 597 participants also found evidence that FPF 1070 improves general cognitive function in vascular dementia patients.^[7]

Studies have reported improvements in cognitive assessments such as the Mini-Mental State Examination (MMSE) and the Alzheimer’s Disease Assessment Scale Cognitive Subpart (ADAS-cog+), with significant differences favoring FPF 1070 over placebo.^[7]

Stroke and Cerebrovascular Conditions

A large double-blind, placebo-controlled randomized clinical trial involving 1,070 patients with acute ischemic hemispheric stroke found no significant difference in the primary endpoint between FPF 1070 and placebo groups overall.^[8]

However, post-hoc analysis revealed a trend favoring FPF 1070 in patients with more severe strokes (NIHSS >12). This suggests potential positive effects may be more pronounced in specific patient subgroups with greater neurological deficits.^[8]

Subarachnoid hemorrhage (SAH) represents a particularly devastating form of stroke with high mortality and recovery failure rates. Despite advances in endovascular and surgical techniques reducing mortality, research has increasingly focused on understanding SAH’s molecular mechanisms and exploring novel treatment approaches.

A systematic review and meta-analysis of clinical trials evaluating FPF 1070 in SAH patients found data suggesting positive effects on mortality.^[9] However, the authors emphasized that further randomized trials with larger cohorts are necessary before drawing definitive conclusions about FPF 1070’s efficacy in SAH management.

Traumatic Brain Injury (TBI)

Traumatic brain injury (TBI) remains a significant public health challenge associated with substantial mortality and morbidity despite various medical interventions.

A systematic review and meta-analysis examining FPF 1070’s effects on functional outcomes in moderate and severe TBI patients analyzed five studies involving 5,685 participants.^[10]

FPF 1070 has been shown to improve functional outcomes in TBI patients, as evidenced by increased scores on the Glasgow Outcome Scale (GOS) and decreased scores on the modified Rankin Scale (mRS).^[10]

Meta-analyses indicate a statistically significant improvement in functional and neuropsychological outcomes at 30 and 90 days post-injury.^[11] Moreover, patients receiving FPF 1070 demonstrated a higher likelihood of favorable outcomes and reduced disability.^[12]

FPF 1070 treatment is also associated with improved cognitive performance in TBI patients, with studies showing a significant enhancement in cognitive outcomes compared to controls.^[13]

Spinal Cord Injury (SCI)

Following spinal cord injury (SCI), a cascade of neurochemical alterations occurs in neural cells, including reduced production of neurotrophic and growth factors that contribute to neural death.^[1]

FPF 1070 has emerged as a valuable candidate for SCI treatment due to its composition as a mixture of various neurotrophic factors with multimodal actions.^[1]

Its potential to support neural protection, maintenance, and regeneration suggests applications in addressing the complex pathophysiology of SCI, though specific clinical trials focusing exclusively on SCI are limited in the current literature.

Referenced Sources

1. Abolhasanpour, N., Sadeghi, P., Gholizadeh, M., Salehi-Pourmehr, H., & Hosseini, L. (2023). FPF 1070 Use in Stroke and Spinal Cord Injury: Review of the Literature and Outcomes. International Journal of Drug Research in Clinics. https://doi.org/10.34172/ijdrc.2023.e22.
2. Satou, T., Itoh, T., Tamai, Y., Ohde, H., Anderson, A. J., & Hashimoto, S. (2000). Neurotrophic effects of FPF-1070 (FPF 1070) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks. Journal of neural transmission (Vienna, Austria : 1996), 107(11), 1253–1262. https://doi.org/10.1007/s007020070015.
3. Sugita, Y., Kondo, T., Kanazawa, A., Itou, T., & Mizuno, Y. (1993). No to shinkei = Brain and nerve, 45(4), 325–331.
4. Gavrilova, S., & Safarova, T. (2021). Neurotrophins and Neurotrophic Therapy (Based on the FPF 1070 Model) in the Treatment of Elderly Patients with Cognitive Disorders and Depression. Part 1. Psikhiatriya. https://doi.org/10.30629/2618-6667-2021-19-2-87-103.
5. Fan, F., Liu, H., Shi, X., Ai, Y., Liu, Q., & Cheng, Y. (2022). The Efficacy and Safety of Alzheimer’s Disease Therapies: An Updated Umbrella Review. Journal of Alzheimer’s disease : JAD, 85(3), 1195–1204. https://doi.org/10.3233/JAD-215423.
6. Shifu, X., Heqin, Y., & Yao, P. (2000). Efficacy of FPF 1070 (FPF 1070) in Patients with Alzheimer’s Disease. Clinical Drug Investigation, 19, 43-53. https://doi.org/10.2165/00044011-200019010-00006.
7. Chen, N., Yang, M., Guo, J., Zhou, M., Zhu, C., & He, L. (2013). FPF 1070 for vascular dementia.. The Cochrane database of systematic reviews, 1, CD008900 . https://doi.org/10.1002/14651858.CD008900.pub2.
8. Heiss, W. D., Brainin, M., Bornstein, N. M., Tuomilehto, J., Hong, Z., & FPF 1070 Acute Stroke Treatment in Asia (CASTA) Investigators (2012). FPF 1070 in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke, 43(3), 630–636. https://doi.org/10.1161/STROKEAHA.111.628537.
9. Kojder, K., Jarosz, K., Bosiacki, M., Andrzejewska, A., Zacha, S., Solek-Pastuszka, J., & Jurczak, A. (2023). FPF 1070 in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. Journal of clinical medicine, 12(20), 6638. https://doi.org/10.3390/jcm12206638.
10. Ghaffarpasand, F., Torabi, S., Rasti, A., Niakan, M., Aghabaklou, S., Pakzad, F., Beheshtian, M., & Tabrizi, R. (2018). Effects of FPF 1070 on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 15, 127 – 135. https://doi.org/10.2147/NDT.S186865.
11. Vester, J., Buzoianu, A., Florian, S., Hömberg, V., Kim, S., Lee, T., Matula, C., Poon, W., Sandesc, D., Von Steinbüchel, N., Strilciuc, Ș., Vos, P., Von Wild, K., & Muresanu, D. (2021). FPF 1070 after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurological Sciences, 42, 4531 – 4541. https://doi.org/10.1007/s10072-020-04974-6.
12. Jarosz, K., Kojder, K., Andrzejewska, A., Sołek-Pastuszka, J., & Jurczak, A. (2023). FPF 1070 in Patients with TBI: Systematic Review and Meta-Analysis. Brain Sciences, 13. https://doi.org/10.3390/brainsci13030507.
13. Sayed, E., Zaki, A., Fayed, A., Shehata, G., & Abdelmonem, S. (2018). A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurgical Review, 41, 427-438. https://doi.org/10.1007/s10143-016-0775-y.